View in EDS

Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype.

Saved in:
Bibliographic Details
Title: Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype.
Authors: Spring, Bryan Q.1,2 (AUTHOR), Watanabe, Kohei1,3 (AUTHOR), Ichikawa, Megumi1 (AUTHOR), Mallidi, Srivalleesha1,4 (AUTHOR), Matsudaira, Tatsuyuki1 (AUTHOR), Timerman, Dmitriy1 (AUTHOR), Swain, Joseph W. R.1 (AUTHOR), Mai, Zhiming1 (AUTHOR), Wakimoto, Hiroaki5 (AUTHOR), Hasan, Tayyaba1,6 (AUTHOR) thasan@mgh.harvard.edu
Source: Photochemistry & Photobiology. Jan2025, Vol. 101 Issue 1, p215-229. 15p.
Subjects: Red light, Cancer stem cells, Surgical margin, Stem cells, Temozolomide
Abstract: Glioblastoma stem cells (GSCs) are potent tumor initiators resistant to radiochemotherapy, and this subpopulation is hypothesized to re‐populate the tumor milieu due to selection following conventional therapies. Here, we show that 5‐aminolevulinic acid (ALA) treatment—a pro‐fluorophore used for fluorescence‐guided cancer surgery—leads to elevated levels of fluorophore conversion in patient‐derived GSC cultures, and subsequent red light‐activation induces apoptosis in both intrinsically temozolomide chemotherapy‐sensitive and ‐resistant GSC phenotypes. Red light irradiation of ALA‐treated cultures also exhibits the ability to target mesenchymal GSCs (Mes–GSCs) with induced temozolomide resistance. Furthermore, sub‐lethal light doses restore Mes–GSC sensitivity to temozolomide, abrogating GSC‐acquired chemoresistance. These results suggest that ALA is not only useful for fluorescence‐guided glioblastoma tumor resection, but that it also facilitates a GSC drug‐resistance agnostic, red light‐activated modality to mop up the surgical margins and prime subsequent chemotherapy. [ABSTRACT FROM AUTHOR]
Copyright of Photochemistry & Photobiology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Glioblastoma stem cells (GSCs) are potent tumor initiators resistant to radiochemotherapy, and this subpopulation is hypothesized to re‐populate the tumor milieu due to selection following conventional therapies. Here, we show that 5‐aminolevulinic acid (ALA) treatment—a pro‐fluorophore used for fluorescence‐guided cancer surgery—leads to elevated levels of fluorophore conversion in patient‐derived GSC cultures, and subsequent red light‐activation induces apoptosis in both intrinsically temozolomide chemotherapy‐sensitive and ‐resistant GSC phenotypes. Red light irradiation of ALA‐treated cultures also exhibits the ability to target mesenchymal GSCs (Mes–GSCs) with induced temozolomide resistance. Furthermore, sub‐lethal light doses restore Mes–GSC sensitivity to temozolomide, abrogating GSC‐acquired chemoresistance. These results suggest that ALA is not only useful for fluorescence‐guided glioblastoma tumor resection, but that it also facilitates a GSC drug‐resistance agnostic, red light‐activated modality to mop up the surgical margins and prime subsequent chemotherapy. [ABSTRACT FROM AUTHOR]
ISSN:00318655
DOI:10.1111/php.13985